Stay updated with breaking news from Phasei Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the...
- ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types - - Company to Host Investor Webcast on June
VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- American Pacific Mining Corp (CSE: USGD / OTCQX: USGDF / FWB: 1QC) (“American Pacific” or...
In our latest #WomenInspiringWomen, we speak with oncologist Dr. Lillian Siu about the advances she and her team are making in immunotherapy.
-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clinical-stage lead candidate INT-1B3 -- InteRNA Technologies, a clinical-stage